Evidence map›Paper›PMID 39509130›Full record

ArticleJAMA network open2024

Neurodevelopment in the First 2 Years of Life Following Prenatal Exposure to Maternal SARS-CoV-2 Infection.

Daphne M Vrantsidis, Marcel van de Wouw, Emily R M Hall, Verena Kuret, Charlie Rioux, Melanie L Conrad, Christine Mesa, Angela Harris, Catherine Lebel, Lianne Tomfohr-Madsen and 1 more

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daphne M VrantsidisDepartment of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Marcel van de WouwDepartment of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Emily R M HallDepartment of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Verena KuretAlberta Children's Hospital Research Institute (ACHRI), Calgary, Alberta, Canada.
Charlie RiouxDepartment of Interdisciplinary Human Sciences, Texas Tech University, Lubbock.
Melanie L ConradInstitute of Medical Psychology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Christine MesaNational Microbiology Laboratory at the J. C. Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Angela HarrisNational Microbiology Laboratory at the J. C. Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Catherine LebelDepartment of Radiology, University of Calgary, Calgary, Alberta, Canada.
Lianne Tomfohr-MadsenDepartment of Educational and Counselling Psychology, and Special Education, University of British Columbia, Vancouver, British Columbia, Canada.
Gerald F GiesbrechtDepartment of Pediatrics, University of Calgary, Calgary, Alberta, Canada.

Funding

CIHR
6 · The paper itself

Abstract

Importance: The effects of prenatal exposure to SARS-CoV-2 infection on child development throughout the first 2 years of life are unknown. Objective: To evaluate whether prenatal exposure to SARS-CoV-2 infection was associated with child neurodevelopmental outcomes during the first 2 years of life. Design, Setting, and Participants: This cohort study used data from the longitudinal, population-based pan-Canadian Pregnancy During the COVID-19 Pandemic cohort, which recruited participants from April 2020 to July 2022. Children were categorized as exposed to prenatal SARS-CoV-2 infection if their birthing parent had a positive polymerase chain reaction test performed by a health authority or as a healthy negative comparison if their birthing parent did not have SARS-CoV-2 antibodies in their postpartum dried blood spot sample. Exposure: Prenatal SARS-CoV-2 infection. Main Outcomes and Measures: The birthing parent reported on their child's temperament at ages 6 and 24 months, developmental milestones at ages 12 and 24 months, and social-emotional milestones at ages 12 and 24 months. Results: A total of 896 children were included, with 96 children who had been exposed to a prenatal SARS-CoV-2 infection (mean [SD] gestational age at birth, 39.20 [1.50] weeks; 45 [47%] male) and 800 were healthy negative comparisons (mean [SD] gestational age at birth, 39.47 [1.54] weeks; 388 [49%] male). In analyses of covariance adjusted for prepregnancy medical conditions and household socioeconomic status, prenatal exposure to SARS CoV-2 infection was associated with slightly higher regulatory control scores, indicating more regulation, at age 6 months (difference in means, 0.19 [95% CI, 0.02-0.36]; P = .03; ηp2 = 0.01). No significant differences were observed for the other neurodevelopmental outcomes. In mixed models adjusted for the same covariates that aimed to examine change in outcomes over time, prenatal SARS-CoV-2 infection exposure was not associated with developmental change in any neurodevelopmental outcomes between ages 6 and 24 months. Conclusions and Relevance: In this longitudinal cohort study of multiple aspects of child neurodevelopment between ages 6 and 24 months, negligible associations between prenatal exposure to SARS-CoV-2 infection and child outcomes were observed. Follow-up research is warranted to determine whether these predominantly null effects persist into later childhood.

Indexed as

COVID-19Maternal ExposureNeurodevelopmental DisordersPrenatal Exposure Delayed EffectsChild, PreschoolFemaleHumansInfantInfant, NewbornMaleModels, Biological

Identifiers

PMID39509130
PMCPMC11544495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.